Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens. 1999; 12 (4): 205S–213S.
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016; 101 (5): 1889–1916.
Stowasser M, Taylor PJ, Pimenta E, et al. Laboratory investigation of primary aldosteronism. Clin Biochem Rev. 2010; 31 (2): 39–56. Cited: in:: PMID: 20498828.
Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the american heart association. Hypertension. 2018; 72 (5): e53–e90. Cited: in:: PMID: 30354828.
Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002; 40 (6): 892–896.
Williams TA, Reincke M. Management of endocrine disease: diagnosis and management of primary aldosteronism: the endocrine society guideline 2016 revisited. Eur J Endocrinol. 2018; 179 (1): R19–R29. Cited: in:: PMID: 29674485.
Ahmed AH, Gordon RD, Taylor PJ, et al. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab. 2011; 96 (6): 1797–1804.
Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021; 103 (4): 213–221.
Lőcsei Z, Horváth D, Rácz K, et al. Progestin-dependent effect of oral contraceptives on plasma aldosterone/renin ratio. Clin Biochem. 2012; 45 (16–17): 1516–1518.
Giribela CRG, Consolim-Colombo FM, Nisenbaum MG, et al. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecological Endocrinol. 2015; 31 (11): 912–915. Cited: in:: PMID: 26172927.
Le Goff CM, Gonzalez-Antuña A, Peeters SD, et al. Migration from RIA to LC-MS/MS for aldosterone determination: implications for clinical practice and determination of plasma and urine reference range intervals in a cohort of healthy Belgian subjects. Clin Mass Spectrom. 2018; 9: 7–17.
Raizman JE, Diamandis EP, Holmes D, et al. A renin-ssance in primary aldosteronism testing: obstacles and opportunities for screening, diagnosis, and management. Clin Chem. 2015; 61 (8): 1022–1027. Cited: in:: PMID: 26106077.
Kfoury B, Cohen JB. Elevated renin and aldosterone levels in a young woman with hypertension. Am J Kidney Diseases. 2020; 75 (6): A11–A13. Cited: in:: PMID: 32446415.
Oelkers W, Blümel A, Schöneshöfer M, et al. Effects of ethinylestradiol on the renin-angiotensin-aldosterone-system and on plasma transcortin in women and men. J Clin Endocrinol Metab. 1976; 43 (5): 1036–1040. Cited: in:: PMID: 993310.
Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol. 2004; 217 (1–2): 255–261.
Blode H, Wuttke W, Loock W, et al. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care. 2000; 5 (4): 256–264. Cited: in:: PMID: 11245553.
Chapman AB, Zamudio S, Woodmansee W, et al. Systemic and renal hemodynamic changes in the luteal phase of the menstrual cycle mimic early pregnancy. Am J Physiol. 1997; 273 (5): F777–782. Cited: in:: PMID: 9374841.
Pizzolo F, Pavan C, Corrocher R, et al. Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy. Am J Hypertens. 2007; 20 (12): 1334–1337.
